SHP-2 Binds to Caveolin-1 and Regulates Src Activity via Competitive Inhibition of CSK in Response to H₂O₂ in Astrocytes

Ara Jo¹, Hyunjoo Park¹, Sung-Hee Lee¹, So-Hee Ahn¹, Hee Ja Kim¹, Eun-Mi Park², Youn-Hee Choi¹*

¹ Department of Physiology, Tissue Injury Defense Research Center, Ewha Womans University School of Medicine, Seoul, Korea, ² Department of Pharmacology, Tissue Injury Defense Research Center, Ewha Womans University School of Medicine, Seoul, Korea

Abstract

Reactive oxygen species (ROS) regulate diverse cellular functions by triggering signal transduction events, such as Src and mitogen-activated protein (MAP) kinases. Here, we report the role of caveolin-1 and Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP-2) in H₂O₂-induced signaling pathway in brain astrocytes. H₂O₂-mediated oxidative stress induced phosphorylation of caveolin-1 and association between p-caveolin-1 and SHP-2. SHP-2 specifically bound to wild-type caveolin-1 similarly to c-Src tyrosine kinase (CSK), but not to phosphorylation-deficient mutant of caveolin-1 (Y14A), and interfered with complex formation between caveolin-1 and CSK. In the presence of CSK siRNA, binding between caveolin-1 and SHP-2 was enhanced by H₂O₂ treatment, which led to reduced Src phosphorylation at tyrosine (Tyr) 530 and enhanced Src phosphorylation at Tyr 419. In contrast, siRNA targeting of SHP-2 facilitated H₂O₂-mediated interaction between caveolin-1 and CSK and enhanced Src phosphorylation at Tyr 530, leading to subsequent decrease in Src downstream signaling, such as focal adhesion kinase (FAK) and extracellular signal-related kinase (ERK). Our results collectively indicate that SHP-2 alters Src kinase activity by interfering with the complex formation between CSK and phosphotyrosine caveolin-1 in the presence of H₂O₂, thus functions as a positive regulator in Src signaling under oxidative stress in brain astrocytes.

Introduction

Reactive oxygen species (ROS), such as hydrogen peroxide (H₂O₂), superoxide (O₂⁻), and hydroxyl radicals (OH⁻), are well-known regulatory signal molecules in the brain [1,2]. Oxidative stress associated with ROS accumulation in the brain leads to the development of diverse neuropathological conditions, including Alzheimer's disease, Parkinson's disease, stroke, and ischemia/reperfusion injury [3,4]. The brain consumes a large amount of O₂ and contains high levels of transition metals, such as iron [5]. Since auto-oxidation of neurotransmitters and secretion of excitotoxic glutamate continuously occur, significant amounts of ROS are produced in the brain compared to in other organs. Moreover, neuronal membranes are enriched in polyunsaturated fatty acids and have a high ratio of membrane surface to cytoplasmic volume [6]. Due to the anatomic structure of brain cells, the extended axonal morphology, and the nonreplicating nature of neurons, the brain is more vulnerable to free radical attacks than other organs [7]. However, how brain cells survive the continuous high ROS and oxidative stress-vulnerable environment, and whether the brain has specific defense mechanisms against ROS or oxygen species are poorly understood.

Astrocytes exist in approximately 50%–90% of the brain and play a crucial role in diverse functions, including protection against metal toxicity and oxidative stress [8–11]. Several recent studies have demonstrated that protein phosphatase activity is increased in reactive glia following cerebral ischemia and that protein phosphatases play a neuroprotective role against oxidative stress [12]. Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP-2) (also known as PTPN11) is a tyrosine phosphatase present in the cytoplasm and highly expressed in the central nervous system (CNS) and neurons and astrocytes [13,14]. SHP-2 reportedly protects neurons from neurodegeneration during focal ischemia/reperfusion injury [15]. Furthermore, SHP-2 inhibition lead to increased programmed cell death of primary cultured neurons in a model of CNS injury [16]. We previously showed that SHP-2 plays an immunomodulatory role against H₂O₂-mediated oxidative stress in brain astrocytes by regulating the activities of STAT-3 and COX-2 [9,17]. In addition, lipid rafts and caveolin-1 are involved in astrocyte-specific intracellular responses linked to the SHP-2-mediated signaling cascade following ROS-induced oxidative stress [17,18]. Caveolin-1, a 21–24-kDa membrane protein, is a major multifunctional scaffolding protein of caveolae that regulates a
Figure 1. H₂O₂ induces caveolin-1 phosphorylation at Tyr 14 in rat primary astrocytes and human astroglioma cells. (A) Rat primary astrocytes, human astroglioma CRT-MG, U87-MG, and U251-MG, and human umbilical vein endothelial cells (HUVECs) were plated and treated with 1 mM H₂O₂ for 10 min, and then whole-cell lysates (WCLs) in cold-RIPA buffer were extracted and subjected to immunoblotting analysis. Blots were probed with antibodies against p-caveolin-1, caveolin-1, and tubulin. HUVECs were utilized as a positive control. Data are representative of at least three experiments. (B) CRT-MG cells were plated and incubated with a range of H₂O₂ concentrations (0–5 mM) for 10 min, and WCLs were extracted using cold RIPA buffer. Antibodies against caveolin-1, p-caveolin-1, and tubulin were used for immunoblotting. Right panel, Densitometric quantification of p-caveolin-1 level was normalized to the level of tubulin. Values are mean ± SD from three experiments. *p<0.05, versus untreated control. (C, D) CRT-MG cells were pretreated with various concentrations of catalase (unit/mL) (C) or NAC (mM) (D) as indicated in the figure for interaction of Caveolin-1/SHP-2 in ROS Signaling.
number of signaling pathways including those involved in cell migration, cell cycle, cell proliferation, cell transformation, and vesicular transport [19,20]. In the brain, caveolin is widely expressed in astrocytes, endothelial cells, gliodendrocytes, Schwann cells, dorsal root ganglia, and hippocampal neurons [21]. Caveolin-1 is phosphorylated at Tyr 14 by Src, Abl, and Fyn in response to a variety of stimuli, including insulin, angiotensin II, osmotic shock, and oxidative stress [22]. In addition, caveolin-1 plays an essential role providing a docking site to anchor various proteins such as e-Src tyrosine kinase (Sak) in several different cell types [23,24]. CSK is known to directly bind to caveolin-1 and suppresses Src kinase activity by inducing Src phosphorylation at the Tyr 530 residue and interfering with Src phosphorylation at Tyr 419 [22,25]. Our recent studies have suggested that H\textsubscript{2}O\textsubscript{2}-mediated oxidative stress induces caveolin-1-SHP-2 complex formation and that caveolin-1 is involved in the ROS-induced activation of SHP-2 [18]. However, the biological significance of caveolin-1-SHP-2 complex formation and the involvement of this complex is involved in astrocyte-specific intracellular responses under oxidative stress remain unclear.

In this study, we present novel evidence and the molecular mechanisms underlying the reciprocal regulation of Src activity by SHP-2 and CSK under H\textsubscript{2}O\textsubscript{2}-mediated oxidative stress in brain astrocytes. We showed that H\textsubscript{2}O\textsubscript{2}-mediated oxidative stress induces the association between caveolin-1 and SHP-2, and that this interaction depends on the phosphotyrosine 14 residue of caveolin-1. In addition, our data show that SHP-2 alters Src activity by interfering with the complex formation between CSK and phosphotyrosine caveolin-1 in the presence of H\textsubscript{2}O\textsubscript{2}, indicating that SHP-2 functions as a positive regulator in Src signaling under oxidative stress in brain astrocytes.

Materials and Methods

Cells
Human astroglialia CRT-MG, U87-MG, and U251-MG cells [26], human umbilical vein endothelial cells (HUVECs), and human embryonic kidney HEK 293T cells were maintained in Dulbecco’s modified Eagle medium (DMEM; WelGENE Inc., Daegu, Korea) containing 10% FBS according to the manufacturer’s instructions for 24 h before treatment with 5 mM H\textsubscript{2}O\textsubscript{2} for 10 min and 300 nM. Cells were allowed to recover in DMEM containing 1% FBS for 48 h before treatment with 5 mM H\textsubscript{2}O\textsubscript{2} for 10 min; the cells were then analyzed by immunoblotting.

Transfection of siRNA
Cells were plated and transfected with green fluorescence protein (GFP) siRNA (Sambull Pharm Co. Ltd., Seoul, Korea) as a control group and human CSK siRNA and human SHP-2 siRNA from Bioneer (Daejeon, Korea) using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions to achieve a final concentration of 300 nM. Cells were allowed to recover in DMEM containing 1% FBS for 48 h before treatment with 5 mM H\textsubscript{2}O\textsubscript{2} for 10 min and were then analyzed by immunoblotting.

Co-immunoprecipitation
Cells were washed with phosphate-buffered saline (PBS) followed by lysis in cold radioimmunoprecipitation assay (RIPA) buffer with protease inhibitors (1% Nonidet-P 40, 0.5% sodium deoxycholate, 10 mM disodium hydrogen phosphate, 150 mM sodium chloride, 1 mM EDTA, 0.1% SDS, 0.5 mM sodium orthovanadate, 10 μg/mL aprotinin, 10 μg/mL leupeptin, and

Reagents and Antibodies
H\textsubscript{2}O\textsubscript{2}, N-acetyl-l-cysteine (NAC), and catalase were purchased from Sigma (St. Louis, MO, USA). PTP inhibitor IV (PTPi IV) was purchased from Calbiochem (San Diego, CA, USA). Recombinant glutathione S-transferase (GST)-SHP-2 and GST-CSK were purchased from Abnova (Taipei, Taiwan). Antibodies against caveolin-1, p-caveolin-1 (pY14) and SHP-2 were obtained from BD Transduction Laboratories (Lexington, KY, USA). Anti-CSK antibody and anti-FAK were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). p-SHP-2 Y542, p-SHP-2 Y580, Src, p-Src Y416, p-Src Y529, and p-FAK antibodies were obtained from Cell Signaling (Danvers, MA, USA). Tubulin antibody was obtained from Sigma. Horseradish peroxidase (HRP)-conjugated secondary antibodies for immunoblotting were obtained from Santa Cruz Biotechnology.

Site-specific Mutagenesis of Caveolin-1 and Transient Transfection
cDNA encoding full-length human caveolin-1 was obtained from Thermo Scientific (Waltham, MA, USA). The Y14A caveolin-1 mutant was generated using a QuickChange site-directed mutagenesis kit (Stratagene, Santa Clara, CA, USA) using PCR. pCMV-SPORT6-caveolin-1 cDNA (25 ng) was used as a template and added to dNTP mix, Pfu buffer, Pfu turbo DNA polymerase and 125 ng of each of the mutagenic primers: sense, 5’-cggagggacatctcgccaccgttcccatccg-3’ and antisense, 5’-egagttggaacgctgctgatctccg-3’. Samples were then incubated at 95°C for 1 min, then for 20 cycles of 95°C for 1 min, 65°C for 4 min, and 68°C for 12 min. The methylated parental DNA template in the PCR product was digested using the DpnI (10 U) restriction enzyme for 3 h at 37°C. The reaction mixture was then directly transformed into XL1 Blue supercompetent Escherichia coli cells (Stratagene) and plated onto LB agar plates containing ampicillin. DNA was extracted from selected clones using the Labopass™ Gel Extraction Kit (Cosmo Genetech Co. Ltd., Seoul, Korea) and sequenced to verify the presence of the desired mutation. After mutagenesis, 1 μg of caveolin-1 wild-type (WT) or Y14A mutant DNA was transfected into HEK 293T cells using VIVAMAGIC transfection reagent (VIVAGEN, Seongnam, Korea) containing 10% FBS according to the manufacturer’s instructions for 24 h before treatment with 5 mM H\textsubscript{2}O\textsubscript{2} for 10 min; the cells were then analyzed by immunoblotting.

Interaction of Caveolin-1/SHP-2 in ROS Signaling

Densitometric quantification of p-caveolin-1 protein levels, normalized to the level of tubulin. Data are expressed as percentage of H\textsubscript{2}O\textsubscript{2}-treated values presented as mean ± SD. (CAT, catalase; Cav-1, caveolin-1; p, phospho). *p<0.05, versus H\textsubscript{2}O\textsubscript{2}-treated cells. Data are representative of three independent experiments.

DOI: 10.1371/journal.pone.0091582.g001
Interaction of Caveolin-1/SHP-2 in ROS Signaling

A

\[ \text{H}_2\text{O}_2 \hspace{1cm} - \hspace{1cm} + \]

IP : Cav-1
WB : CSK

IP : Cav-1
WB : Cav-1

B

\[ \text{H}_2\text{O}_2 \hspace{1cm} \begin{array}{c} \text{WT} \\ \text{Y14A} \end{array} \hspace{1cm} \begin{array}{c} \text{WT} \\ \text{Y14A} \end{array} \]

IP : CSK
WB : Cav-1

IP : Cav-1
WB : CSK

\[ \text{H}_2\text{O}_2 \hspace{1cm} \begin{array}{c} \text{Mock} \\ \text{WT} \\ \text{Y14A} \end{array} \hspace{1cm} \begin{array}{c} - \\ - \\ - \end{array} \hspace{1cm} \begin{array}{c} + \\ + \\ + \end{array} \]

CSK
p-Cav-1
Cav-1
Tubulin
Input
Figure 2. H$_2$O$_2$-mediated association of CSK and caveolin-1 is dependent on the phosphorylation of caveolin-1 at Tyr 14. (A) CRT-MG cells were treated with or without H$_2$O$_2$ for 10 min, and whole-cell lysates (WCLS) were extracted. A total of 700 µg of WCLS was immunoprecipitated with an anti-caveolin-1 antibody. Immunoprecipitates were analyzed by immunoblotting with anti-CSK and anti-caveolin-1 antibodies. (B) Human embryonic kidney cell line HEK 293T cells were transfected with empty vector (Mock), wild-type (WT) and mutant caveolin-1 (Y14A). After 24 h, cells were treated with 5 mM H$_2$O$_2$ for 10 min or left untreated and lysed in RIPA buffer. WCLs (700 µg) were preclarified and immunoprecipitated with anti-CSK and anti-caveolin-1 antibodies and then analyzed by immunoblotting. Input (5%) is shown (Cav-1, caveolin-1 and pY14-caveolin-1). Data are representative of at least 3 experiments.

doi:10.1371/journal.pone.0091582.g002

1 mM phenylmethylsulfonyl fluoride) for 1 h on ice. Total lysates (700 µg) were pre-cleared by incubating with protein A-agarose beads (Biovision Inc., Mountain View, CA, USA) for 3 h at 4°C. After centrifugation, cleared lysates were incubated with 1 µg of anti-caveolin-1, anti-SHP-2, and anti-CSK antibodies at 4°C overnight, and precipitated with protein A-agarose beads for 3 h at 4°C. Immunoprecipitated proteins were separated by 10% or 12% SDS-PAGE, and input proteins were analyzed by immunoblotting as described.

Immunoblot Analysis

Cells were lysed in ice-cold RIPA buffer containing protease inhibitors for 1 h on ice. Total lysates were centrifuged (12,000 x g) at 4°C for 30 min and resolved by 10% or 12% SDS-PAGE. Separated proteins were transferred to polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA, USA), and then blots were probed with caveolin-1, p-caveolin-1, SHP-2, p-SHP-2, CSK, Src, p-Src, ERK, p-ERK, FAK, p-FAK and tubulin antibodies. After incubating with specific secondary antibodies, the blots were exposed to blue X-ray film (AGFA, Mortsel, Belgium) by using an enhanced chemiluminescence system (Amersham, Buckinghamshire, UK).

In situ Proximity Ligation Assay (PLA)

Protein-protein interactions were detected using the Duolink II in situ proximity ligation assay (PLA) Kit (Olink Bioscience, Uppsala, Sweden). Cells were plated and treated with or without 5 mM H$_2$O$_2$ for 10 min, fixed with 100% methanol at −20°C for 30 min, and then incubated overnight with antibodies against caveolin-1 and SHP-2 at 1:100 dilution. After washing, the PLA probe PLUS against SHP-2 and PLA probemaker probe against caveolin-1 were incubated for 3 h at 37°C and the ligases (1 U/µL) diluted at 1:40 were incubated for 2 h at 37°C. Circular oligonucleotides were amplified using polymerase (10 U/µL) diluted at 1:80 for 100 min at 37°C. Samples were viewed using a Carl Zeiss confocal microscope (Carl Zeiss AG, Oberkochen, Germany). Nuclei were stained with VECTASHIELD HardSet™ mounting medium with DAPI (Vector Laboratories Inc., Burlingame, CA, USA). Experiments were repeated 4 times and showed similar results.

PepSPOTs Assay

Identification of binding sites for recombinant SHP-2 and CSK in the caveolin-1 protein was performed using PepSPOTs (JPT Peptide Technologies GmbH, Berlin, Germany). Synthetic peptide sequences of caveolin-1 (1–85 and 1–28) were used in this study. The peptide library contained either 13-mer peptides that overlapped by 5 residues or 13-mer peptides that overlapped by 8 residues. Each spot carried approximately 5 nmol of peptide covalently bound to the cellulose-betaalanine-membrane (N-terminus: acetyl). Two identical membranes were incubated overnight with either recombinant GST-SHP-2 (rGST-SHP-2) or GST-CSK (rGST-CSK) respectively, and immunoblotting was performed to detect rGST-SHP-2/caveolin-1 peptide and rGST-CSK/caveolin-1 peptide interactions.

Surface Plasmon Resonance (SPR)

SPR was performed on a SPRmicro system (K-MAG, Daejeon, Korea). A G1 chip (bare surface gold chip) was dipped into a 3 mM N-hydroxysuccinimide self-assembled monolayer to form covalent bonds among protein amine groups. After washing with ethanol, the chip was purged with N$_2$ gas. Recombinant GST-SHP-2 or GST-CSK was mixed with 20% ethylene glycol and then spotted onto the chip. Ligands were reacted on room temperature for 12 h to allow the ligands to become fixated onto the chip. After the reaction, the ligands were removed by washing with 1 xTris-buffered saline (TBS), and purged with N$_2$ gas. SPR signal baselines were stabilized using 1 xTBS running buffer, and different dilutions of caveolin-1 phosphopeptides (Cav-1 pY 14, GHL-pY-TVPIREQGN) in buffer were injected at a flow rate of 20 µL/min. Response unit (RU) alterations following sample reactions were analyzed by comparing affinities to the chip surface. Experiments were conducted by switching from samples immobilized on the chip (Cav-1 pY 14) to injected samples (rGST-CSK or rGST-SHP-2). Experiments were repeated twice and showed similar results. Equilibrium binding curves and RU values are shown.

Protein Expression and Purification

Human SHP-2 and CSK fusion constructs were produced by consecutively subcloning the protein coding regions of SHP-2 and CSK into the pGEX-6p-1 vector (GE healthcare, Piscataway, NJ, USA). Using these constructs, human SHP-2 and CSK were overexpressed in Escherichia coli (BL21) as soluble. Briefly, the transformed bacteria were grown in LB medium with 0.1 mg/ml ampicillin at 37°C to an A600 of 0.6, and then cultured for an additional overnight at 27°C after being induced with 0.5 mM IPTG (Duchefa Biochemie, Netherlands). The cells were harvested by centrifugation at 8000 g for 20 min, resuspended in PBS pH 7.4, and then disrupted by ultrasonication. The supernatant was purified with glutathione agarose 4B (Incospharm, Daejeon, South Korea) in PBS pH 7.4. The bound proteins were eluted with a linear gradient 10 mM glutathione in 50 mM Tris (pH 8.0). All proteins were concentrated with a Centricon apparatus (Millipore, Darmstadt, Germany). Proteins were quantitated with the Bradford assay, then filtered and stored at −70°C until use.

Flow Cytometry

Conjugation of 1–50 mer caveolin-1 peptide (PEPTRON, Daejeon, South Korea) to carbosulfonyl beads (Bangs Laboratories, Fishers, IN, USA) using 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) [27]. After washing the carbosulfonyl beads with distilled water (DW), the carbosulfonyl beads were incubated with caveolin-1 peptide 25 µg/ml (1–50) and 1% EDC (Fierce Biotechnology, Rockford, IL, USA) for overnight at 37°C with shaking. Then we add 10 mM of glycine and 10 mM glucose for 30 min at RT. Caveolin-1 peptide Conjugated beads were incubated with recombinant CSK or SHP-2 protein for 1 h at RT with shaking. After wash with PBS, beads were incubated with 1 µg of anti-CSK or anti-SHP-2 antibodies at 4°C for 1 h. The beads were then incubated with FITC-conjugated goat anti-rabbit
Figure 3. H₂O₂ induces SHP-2-caveolin-1 complex formation. (A) Complex formation between caveolin-1 and SHP-2 in CRT-MG cells as investigated by in situ proximity ligation assay (PLA). CRT-MG cells were incubated for 10 min with 5 mM H₂O₂, fixed, and then incubated overnight with antibodies against caveolin-1 and SHP-2. After washing, the PLA probe PLU5 and PLA Probemaker probe were incubated for 3 h at 37°C and diluted ligases at 1:40 were incubated for 2 h at 37°C. Circular oligonucleotides were amplified using polymerase for 100 min at 37°C. Nuclei were stained with DAPI. The experiments were repeated 4 times with similar results. Bars = 20 μm. (B) pCMV-SPORT6, Caveolin-1 WT or caveolin-1 Y14A DNA were transiently transfected into HEK 293T cells. Next, 24 h after transfection, cells were incubated with 5 mM H₂O₂ for 10 min. WCLs (700 μg) were subjected for immunoprecipitation using the anti-caveolin-1 and anti-SHP-2 antibodies and analyzed by immunoblotting. Input (5%) is shown. Data are representative of at least 3 experiments.

doi:10.1371/journal.pone.0091582.g003

Statistical Analysis

Statistical analyses were performed using the Student’s t test to compare between sample groups, and ANOVA was used to determine differences among multiple groups. Statistical significance of the data was set at P<0.05.

Results

H₂O₂ Induces Caveolin-1 Phosphorylation at Tyr 14 in Brain Astrocytes

Previous studies demonstrated that H₂O₂ induces the phosphorylation of caveolin-1 at Tyr 14 in bovine pulmonary artery endothelial and placenta artery endothelial cells [28–30]. To determine whether H₂O₂ induces the phosphorylation of caveolin-1 in brain astrocytes, rat primary astrocytes, human astrogloma cells (CRT-MG, U87-MG, and U251-MG) and HUVECs were treated with 1 mM H₂O₂ for 10 min and examined by immunoblotting for p-caveolin-1. H₂O₂ induced the phosphorylation of caveolin-1 in the presence of H₂O₂ in primary astrocytes, astrogloma cells, and endothelial cells (Fig. 1A). H₂O₂ induced a dose-dependent increase in the level of Tyr-phosphorylated caveolin-1 up to a concentration of 5 mM in CRT-MG cells, with no change in the amount of caveolin-1 or tubulin (Fig. 1B). To determine whether H₂O₂ is directly involved in caveolin-1 phosphorylation at Tyr 14, cells were treated with catalase and the potent ROS scavenger NAC. Both catalase and NAC considerably suppressed H₂O₂-induced caveolin-1 phosphorylation in a dose-dependent manner (Fig. 1C and 1D). These results indicate that Tyr 14 of caveolin-1 is phosphorylated in response to H₂O₂ in brain astrogloma cells, which agrees with the results of previous studies using bovine pulmonary artery endothelial cells and placenta artery endothelial cells.

H₂O₂-mediated Association of CSK and Caveolin-1 is Dependent on the Phosphorylation of Caveolin-1 at Tyr 14 in Human Astrogloma Cells

Caveolin-1 has been implicated as a CSK adapter and several reports demonstrated that CSK interacted only with Tyr 14-phosphorylated caveolin in response to VEGF, angiotensin II, insulin, v-Abl, EGF, and oxidative stress [22,31,32]. To confirm whether CSK interacts with Tyr 14-phosphorylated caveolin in response to H₂O₂ in astrocytes, a co-immunoprecipitation assay was performed using total lysates from CRT-MG cells. As shown in Fig. 2A, complex formation occurred between caveolin-1 and CSK following H₂O₂ treatment of CRT-MG cells. To explore the role of the caveolin-1 Tyr 14 residue in the interaction between caveolin-1 and CSK, HEK 293T cells were used because they are known to express caveolin-1 at a very low level. The cells were transfected with plasmids encoding either WT caveolin-1 or a phosphorylation-deficient caveolin-1 mutant (Y14A); treated with or without H₂O₂, and then co-immunoprecipitated with either anti-CSK or anti-caveolin-1 antibodies. An interaction between CSK and WT caveolin-1, but not Y14A mutant caveolin-1, was observed in the presence of H₂O₂ (Fig. 2B). These results indicate that H₂O₂-induced formation of the caveolin-1/CSK complex is dependent on the Tyr 14 residue of caveolin-1.

H₂O₂ Induces SHP-2-caveolin-1 complex Formation in Human Astrogloma Cells

We previously showed that SHP-2 is translocated into lipid rafts and activated in response to H₂O₂, while caveolin-1 is involved in ROS-induced activation of SHP-2 activation through protein-protein interactions in brain astrocytes [17]. To confirm H₂O₂-induced complex formation between SHP-2 and caveolin-1, an in situ PLA, which enables the detection of direct protein-protein interactions between 2 proteins by visualization in situ as a fluorescent red dot [33], was performed using CRT-MG astrogloma cells. Images obtained from the PLA showed that a direct interaction between SHP-2 and caveolin-1 (indicated by red dots) occurred in the presence of H₂O₂ in CRT-MG cells (Fig. 3A). To test whether this H₂O₂-induced interaction between SHP-2 and caveolin-1 depends on the Tyr 14 residue of caveolin-1, similar to the interaction between CSK and caveolin-1, a co-immunoprecipitation assay was performed in HEK 293T cells that were transfected with either WT or Y14A caveolin-1 DNA in the absence or presence of H₂O₂. As shown in Fig. 3B, SHP-2 interacted with WT caveolin-1, but not mutant caveolin-1, and only in the presence of H₂O₂. These results indicate that SHP-2 forms a complex with caveolin-1 in response to H₂O₂ in brain astrocytes and that H₂O₂-induced caveolin-1 and SHP-2 complex formation is dependent on the Tyr 14 residue of caveolin-1.

Both SHP-2 and CSK Specifically Bind to Tyr-phosphorylated Caveolin-1 (Tyr 14)

Since both SHP-2 and CSK bound to caveolin-1 by recognizing the specific phosphorylated Tyr 14 residue, other tyrosine residues in caveolin-1 were examined to determine if they also mediate binding to SHP-2 or CSK. Thirteen- amino acid-long synthetic peptides of caveolin-1 on PepSPOT were used for binding analysis. Four Tyr residues (Tyr 6, Tyr 14, Tyr 25, and Tyr 42) were phosphorylated (marked in bold, Fig. 4B, left). Duplicate membranes containing bound caveolin-1 peptides were incubated with either 1 μg recombinant GST-SHP-2 (rGST-SHP-2) or GST-CSK (rGST-CSK) and washed, and the binding of SHP-2 or CSK to the caveolin-1 peptides was analyzed by immunoblotting. PepSPOT analysis showed that only 1 spot of bound recombinant SHP-2 was detected, corresponding to residues 9–21 of caveolin-1 (spot 2), which included Tyr 14. Similar to SHP-2, strong binding between caveolin-1 peptides and recombinant CSK was detected in spot 2; however, weak binding was also observed in spots 5 and 9. Based on these experiments with pairs of synthetic nonpho-
sphorylated-Tyr and corresponding phosphorylated-Tyr 13-mer peptides of caveolin-1 (1–28) spotted on the membrane, strong binding of both rGST-SHP-2 and rGST-CSK to caveolin-1 was observed only in spots containing phosphorylated Tyr 14 residues (Fig. 4C).

SPR Analyses of SHP-2 and CSK Binding to Phosphorylated-Tyr Peptides of Caveolin-1

To confirm that direct interaction occurs between SHP-2 and caveolin-1 and to compare the binding affinity of SHP-2 and CSK to phosphorylated-Tyr caveolin-1, SPR experiments were performed.
formed using a SPRmicro system (K-MAC, Daejeon, Korea) as described in Materials and Methods. Real-time association kinetics of either recombinant GST-SHP-2 (rGST-SHP-2) or rGST-CSK immobilized on a G1 chip with a synthetic peptide phosphorylated at a Tyr residue corresponding to Tyr 14 of caveolin-1 (Cav-1 pY14, GHL-pY-TVPIREQGN) were analyzed by increasing peptide concentrations from 10 to 1,000 µg/mL. As shown in Fig. 5A, both rGST-SHP-2 and rGST-CSK were found to bind to Cav-1 pY14 with high affinity and there was no significant difference in their kinetic rates or RUs. Reverse-SPR experiments were performed by immobilizing Cav-1 pY14 on the chip and using rGST-SHP-2 or rGST-CSK as a probe (Fig. 5B); the results were similar to those observed in Fig. 5A. Next, we performed bead-based flow cytometric binding assay to confirm the direct interaction between SHP-2 and CSK to p-caveolin-1. Fifty-amino acid-long synthetic peptides of caveolin-1 (1–50 a.a.) were conjugated to carboxyl beads using EDC as described in Materials and Methods. Caveolin-1 peptide conjugated beads were incubated with either CSK or SHP-2 protein (1–10 µg), anti-CSK, or anti-SHP-2 antibodies and then incubated with FITC- or Alexa 488-conjugated IgG antibodies. As shown in Fig. 5C, both SHP-2 and CSK significantly bound to p-caveolin-1 peptide, in consistent to PepSPOTs assay (Fig. 4) and SPR analyses.

siRNA Targeting CSK Facilitates H2O2-mediated Binding between Caveolin-1 and SHP-2

Since we found that both SHP-2 and CSK directly bind to caveolin-1, we next examined whether SHP-2 and CSK compete with each other for binding to caveolin-1 by performing SHP-2 and CSK depletion using siRNA and co-immunoprecipitation assays in the presence or absence of H2O2. In the presence of CSK siRNA, the association between caveolin-1 and SHP-2 was dramatically increased following H2O2 treatment compared to that of the control group (Fig. 6, upper panel, compare lanes 4 and 2). In addition, in the presence of SHP-2 siRNA, H2O2-induced formation of caveolin-1/CSK complex was slightly enhanced compared to that of the control (Fig. 6, lower panel, compare lanes 6 and 2). To confirm whether SHP-2 competes with CSK for binding to p-caveolin-1, flow cytometric competitive binding assay was performed. Caveolin-1 peptide conjugated beads were incubated with 10 µg of recombinant CSK protein with or without SHP-2 protein (1–100 µg). After wash, beads were incubated with anti-CSK antibody and FITC-conjugated goat anti-rabbit IgG antibody, and then analyzed by flow cytometry. The amount of bound CSK on the p-caveolin-1 peptide conjugated beads was reduced by adding increasing concentrations of SHP-2 protein (1–100 µg). These findings indicate that knockdown of CSK facilitates H2O2-induced complex formation between caveolin-1 and SHP-2 and that reciprocal binding of SHP-2 and CSK to caveolin-1 occurred in H2O2-stimulated astrocytes.

SHP-2 and CSK Reciprocally Regulate H2O2-induced Src Activation

CSK is known to directly bind to caveolin-1 and suppress c-Src kinase activity by inducing c-Src phosphorylation at Tyr 530 [22]. To test whether specific siRNA-mediated depletion of CSK or SHP-2 under oxidative stress affects Src activity, CRT-MG cells were transfected with CSK or SHP-2 siRNA for 48 h, treated with or without H2O2 for 10 min, and immunoblotted with anti-Src, anti-p-Src Y416 (Y419 in human), anti-p-Src Y27 (Y350 in human), anti-CSK, anti-SHP-2, anti-caveolin-1, and anti-tubulin antibodies. In the presence of CSK siRNA, the phosphorylation level of Src Y350 decreased following H2O2 treatment (Fig. 7A, second panel, compare lanes 4 and 2), while the phosphorylation level of Src Y419 was significantly increased under H2O2 treatment compared to that of the GFP siRNA-transfected cells (CON siRNA; first panel, compare lanes 4 and 2). In contrast, in the presence of SHP-2 siRNA, the level of p-Src Y530 activity upon H2O2 treatment was comparable to that of the control (Fig. 7A, second panel, compare lanes 6 and 2); however, p-Src Y419 phosphorylation was significantly reduced following H2O2 treatment compared to that of the CSK and GFP siRNA groups (first panel, compare lanes 6 and 2, 4). To examine the effect of siRNA-mediated depletion of CSK or SHP-2 on Src-downstream signaling in response to H2O2, the same lysates were analyzed by immunoblotting against p-ERK. In the presence of CSK siRNA, the phosphorylation level of ERK was increased by H2O2 treatment (Fig. 7A, fourth panel, compare lanes 4 and 2), while the phosphorylation level of ERK was decreased following H2O2 treatment in the presence of SHP-2 siRNA, compared to that of CSK and GFP siRNA-transfected cells (fourth panel, compare lanes 6 and 2, 4).

Inhibition of SHP-2 by PTPi IV Attenuates the H2O2-induced Activation of Src-mediated ERK and FAK Activation

To verify the effects SHP-2 inhibition on Src activity in astrocytes, CRT-MG cells were pretreated with a pharmacological inhibitor of SHP-2, PTP inhibitor IV (PTPi IV), at various concentrations (0–10 µM) for 30 min, treated with or without 5 mM H2O2 for 10 min, and analyzed by immunoblotting using antibodies against p-SHP-2, SHP-2, p-Src, and Src. PTPi IV significantly reduced SHP-2 phosphorylation at Y542 and Y580 (Fig. 7B, compare lanes 2, 3, and 4), which was similar to the results of our previous studies [17]. Additionally, PTPi IV induced a dose-dependent decrease in H2O2-mediated phosphorylation of Src at Tyr 419; however, no significant change was detected for Tyr 530 phosphorylation of Src. Next, to examine whether inhibition of SHP-2 affects the Src-mediated downstream signaling pathway, immunoblotting against downstream targets such as FAK and ERK was performed. As shown in Fig. 7B, the SHP-2 inhibitor PTPi IV strongly inhibited both FAK and ERK phosphorylation.
A

|       | CON siRNA | CSK siRNA | SHP-2 siRNA |
|-------|-----------|-----------|-------------|
| $\text{H}_2\text{O}_2$ | - | + | - | + |

- IP : Cav-1
- WB : SHP-2
- IP : Cav-1
- WB : CSK
- IP : Cav-1
- WB : Cav-1

B

![Graph showing cell fluorescence intensity](image)

- **CON**
- CSK 10μg/ml
- SHP-2 1μg/ml + CSK 10μg/ml
- SHP-2 1μg/ml + CSK 10μg/ml
- SHP-2 100μg/ml + CSK 10μg/ml

**CSK FL1-H**

**Count**
Discussion

In this study, we have investigated the molecular mechanism for the positive role of SHP-2 in regulating Src activity in response to \( \text{H}_2\text{O}_2 \)-mediated oxidative stress in brain astrocytes. Our results provide initial evidence that \( \text{H}_2\text{O}_2 \) triggers complex formation between caveolin-1 and SHP-2, which interferes with the association between caveolin-1 and CSK and leads to enhanced activation of Src, at least in brain astrocytes.

Because both SHP-2 and CSK interacted with phospho-Tyr 14 of caveolin-1 (Fig. 4 and 5) and \( \text{H}_2\text{O}_2 \)-induced Src phosphorylation was affected by SHP-2 and CSK in an inverse manner (Fig. 7), we propose that SHP-2 competitively inhibits the binding of CSK to caveolin-1 and functions as a positive regulator of the Src signaling pathway (Fig. 8). \( \text{H}_2\text{O}_2 \) induces phosphorylation of caveolin-1 at Tyr 14, which provides a docking site to cytoplasmic proteins, such as CSK and SHP-2. When CSK interacts with phosphorylated caveolin-1, CSK induces phosphorylation of Src \( \text{Y}530 \) to inactivate the catalytic activity of Src. However, if SHP-2 binds to phospho-caveolin-1, SHP-2 interferes with complex formation between caveolin-1 and CSK, leads to a decrease in phosphorylation of Src \( \text{Y}530 \) and an increase in phosphorylation of Src \( \text{Y}419 \), and results in sustained Src activation. These results indicate that SHP-2 and CSK reciprocally regulate \( \text{H}_2\text{O}_2 \)-induced Src activity through competitive binding to caveolin-1 in brain astrocytes.

We observed that SHP-2 and CSK showed similar binding affinities to p-caveolin-1 (Fig. 5) and competed with each other for access to p-Y14 caveolin-1 (Fig. 6B). In our system, SHP-2 appeared to be an adaptor protein in \( \text{H}_2\text{O}_2 \)-mediated Src signaling rather than a tyrosine phosphatase. Since SHP-2 is not a kinase, phosphorylation of Src \( \text{Y}419 \) may result from abrogating CSK action rather than inducing direct phosphorylation by SHP-2. SHP-2 is known to be either a positive or negative regulator in cellular signal transduction pathways by functioning as an adaptor protein [34]. SHP-2 exerts its negative regulatory effects through dephosphorylation or deactivation of tyrosine-phosphorylated molecules such as JAK/STATs and TrkB receptor [35,36]. However, positive regulatory functions have also been demonstrated, as are seen in transducing signals initiated by interleukin-2 or several growth factors such as insulin, epidermal growth factor, platelet-derived growth factor, and fibroblast growth factor, which leads to activation of the MAP kinase pathway [37,38]. Although the functions of SHP-2 in cytokine and growth factor signaling have recently been determined, the precise mechanisms by which SHP-2, a protein tyrosine phosphatase, positively regulates these intracellular signaling pathways are not well understood. In this study, we identified the putative mechanism by which SHP-2 function as an adaptor protein that competes with CSK for binding to the phosphorylated Tyr 14 residue of caveolin-1 in the presence of \( \text{H}_2\text{O}_2 \).

Caveolin-1 is a major multifunctional scaffolding protein of caveolae that provides a docking site to anchor various proteins, regulates a variety of signaling molecules, and modulates downstream signaling pathways negatively or positively [23,39]. In this study, caveolin-1 acts as a docking protein for both CSK and SHP-2 in response to \( \text{H}_2\text{O}_2 \), suggesting that caveolin-1 may function as either positive or negative regulator in Src/ERK signaling pathways depending on the kind of binding partners. In retinal ganglion cells, caveolin-1 binds to SHP-2 enabling SHP-2-TrkB interaction, leading to TrkB receptor deactivation [36]. In brain astrocytes, SHP-2 forms complex with caveolin-1 and positively regulates Src signaling, by interfering the binding of CSK to caveolin-1. These results suggest that caveolin-1 may have distinct physiological functions in different cell types.

In both rat primary astrocytes and human astroglialoma cells, \( \text{H}_2\text{O}_2 \) strongly induced phosphorylation of caveolin-1 at Tyr 14 (Fig. 1), which is similar to the results of previous studies performed in bovine pulmonary artery endothelial cells and placenta artery endothelial cells [20–30]. We found that catalase and NAC were able to suppress \( \text{H}_2\text{O}_2 \)-induced caveolin-1 phosphorylation; however, the effect of NAC was modest compared to catalase. NAC is considered as a nonspecific ROS scavenger due to its reducing property and free radical scavenging property through increasing intracellular level of glutathione [40]. Our data demonstrate that catalase, an enzyme which directly catalyzes hydrogen peroxide, completely abrogates \( \text{H}_2\text{O}_2 \)-induced caveolin-1 phosphorylation, thereby suggesting that the oxidative stress mediated by exogenously treated, in other hands, externally generated \( \text{H}_2\text{O}_2 \) directly induced caveolin-1 phosphorylation in astrocytes. Tyrosine phosphorylation at the 14th residue of caveolin-1 plays an essential role in providing a docking site to anchor various proteins, e.g., RhoA, E-cadherin, G-proteins, and CSK [23,24,39]. CSK, a cytoplasmic multi-domain tyrosine kinase, is recruited to the plasma membrane through its interaction with phosphorylated caveolin-1 at Tyr 14 in response to growth factors and oxidative stress. This CSK docking process enables phosphorylation of Tyr 530 in Src, which leads to inactivation of Src activity [22,41]. Our results demonstrate that the cytoplasmic phosphatase SHP-2 behaves similar to CSK, as SHP-2 translocates and interacts with phosphorylated caveolin-1 in response to \( \text{H}_2\text{O}_2 \). Complex formation between SHP-2 and caveolin-1 disturbs both the binding of CSK to caveolin-1 and the negative regulation of Src by CSK. A previous report showed that SHP-2 regulates c-Src activation by controlling CSK/VE-cadherin dynamic interactions in response to vascular endothelial growth factor [42]. However, the exact mechanisms by which SHP-2 stimulates CSK dissociation have not been clarified. Here, we propose that SHP-2 is involved in the regulation of Src as an adaptor protein that competes with CSK, at least in brain astrocytes.

Interestingly, our results showed that \( \text{H}_2\text{O}_2 \)-induced Src activation leads to phosphorylation of ERK 1/2 and FAK, and this phosphorylation was reduced in astrocytes by PTPi IV and SHP-2 siRNA (Fig. 7A and 7B). These results indicate that SHP-2 functions as an upstream signaling molecule of Src activation in \( \text{H}_2\text{O}_2 \)-induced signal transduction. Since Src activation was shown to be involved in the activation of FAK in different types of cells, which plays an important role in focal adhesion and cell motility [43,44], our results suggest that SHP-2 may play an important role in regulating cell motility and cell survival by modulating Src/FAK and Src/ERK signaling pathways. Previously, it was...
Figure 7. SHP-2 and CSK reciprocally regulate H$_2$O$_2$-induced Src activation. (A) CRT-MG cells transfected with GFP siRNA, CSK siRNA, and SHP-2 siRNA for 48 h were treated with 5 mM H$_2$O$_2$ for 10 min and whole-cell lysates were extracted and immunoblotted using an anti-p-Src Y419, anti-p-Src Y530, anti-Src, anti-pERK1/2, anti-ERK, anti-CSK, anti-SHP-2, anti-caveolin-1, and anti-p-caveolin-1 antibodies. Tubulin was evaluated as a loading control. Bottom panel, Densitometric quantification of p-Src Y419 levels (empty bars) and p-Src Y530 levels (filled bars), normalized to the level of total Src. Results are expressed as percentage of H$_2$O$_2$-treated values in control siRNA presented as mean ± SD. (*p$<$0.05 vs. H$_2$O$_2$-treated cells transfected with control siRNA; #p$<$0.05 between SHP-2 siRNA-transfected cells and CSK siRNA-transfected cells; n = 3). (B) Inhibition of SHP-2 by PTPi IV attenuated the H$_2$O$_2$-induced activation of the Src signaling pathway. CRT-MG cells were treated with 5 mM H$_2$O$_2$, or not for 10 min in the presence of 5 or 10 mM PTPi IV for 30 min, and lysed in cold-RIPA buffer. Antibodies against p-SHP-2, SHP-2, p-Src, Src, p-FAK, FAK, p-ERK, ERK, and tubulin were used for immunoblotting. Bottom panel, Densitometric quantification of p-Src Y419 levels (empty bars) and p-Src Y530 levels (filled bars), normalized to the level of total Src. Data are expressed as percentage of H$_2$O$_2$-treated values presented as mean ± SD (n = 3). *p$<$0.05 vs. H$_2$O$_2$-treated cells. (p, phospho).

doi:10.1371/journal.pone.0091582.g007
reported that CSK binds to paxillin in focal adhesions in fibroblasts and epithelial cells and triggers Src inactivation and subsequent downregulation of FAK activation [45,46]. CSK siRNA decreased the phosphorylation of Src Y530 and dramatically increased the phosphorylation of Src Y419 following H2O2 treatment (Fig. 7A), which is in contrast to data obtained using SHP-2 siRNA. These results suggest that SHP-2 may function as a positive regulator of Src kinase, which is negatively regulated by CSK. Thus, we conclude that SHP-2 competes with CSK for binding to caveolin-1 and triggers Src activation and subsequent ERK and FAK phosphorylation. Because SHP-2 is known to be highly expressed in the CNS [13,14] and is reported to protect neurons from neurodegeneration during oxidative stress [15], it is important to elucidate how SHP-2-mediated modulation of Src/FAK and Src/ERK signaling contributes to neuroprotection against large amounts of ROS, which are produced throughout the brain, and which downstream genes and proteins are specifically affected by these signal transduction pathways.

In summary, this study showed that SHP-2 bound to caveolin-1 and contributed to the regulation of Src activity via the competitive inhibition of CSK in the presence of H2O2 in astrocytes. Our results suggest that SHP-2 may be one of candidate targets for oxidative brain damage, as a prominent regulator of Src signaling against excessive ROS.

Author Contributions
Conceived and designed the experiments: AJ HP YHC. Performed the experiments: AJ HP SHL SHA HJK. Analyzed the data: AJ HP HJK EMP YHC. Contributed reagents/materials/analysis tools: EMP. Wrote the paper: AJ HP YHC.

References
1. Groeger G, Quiney C, Cotter TG (2009) Hydrogen peroxide as a cell-survival signaling molecule. Antioxid Redox Signal 11: 2655–2671.
2. Tsatmali M, Walcott EC, Makarenkova H, Crossin KL (2006) Reactive oxygen species modulate the differentiation of neurons in clonal cortical cultures. Mol Cell Neurosci 33: 345–357.
3. Emerit J, Edeas M, Bricaire F (2004) Neurodegenerative diseases and oxidative stress. Biomed Pharmacother 58: 39–46.
4. Reynolds A, Laurie C, Mosley RL, Gendelman HE (2007) Oxidative stress and the pathogenesis of neurodegenerative disorders. Int Rev Neurobiol 82: 297–325.
5. Uttara B, Singh AV, Zamboni P, Mahajan RT (2009) Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol 7: 65–74.
6. Wang X, Michaelis EK (2010) Selective neuronal vulnerability to oxidative stress in the brain. Front Aging Neurosci 2: 12.
7. Gadotli N, Goebel HH (2011) Oxidative stress and free radical damage in neurology. New York: Humana Press. viii, 323 p.
8. Hirrlinger J, Dringen R (2010) The cytosolic redox state of astrocytes: Maintenance, regulation and functional implications for metabolite trafficking. Brain Res Rev 63: 177–188.
9. Park SJ, Lee JH, Kim HY, Choi YH, Park JS, et al. (2012) Astrocytes, but not microglia, rapidly sense H₂O₂ via STAT6 phosphorylation, resulting in cyclooxygenase-2 expression and prostaglandin release. J Immunol 188: 5132–5141.

10. Parpura V, Heneka MT, Montanta V, Oliet SH, Schousboe A, et al. (2012) Glial cells in pathophysiology. J Neurochem 121: 4–27.

11. Tiffany-Castiglioni E, Hong S, Qian Y (2011) Copper handling by astrocytes: insights into neurodegenerative diseases. Int J Dev Neurosci 29: 811–818.

12. Gee CE, Marcou JM (2005) Protein phosphatases and their potential implications in neuroprotective processes. Cell Mol Life Sci 62: 1120–1130.

13. Suzuki T, Matzaki T, Mizoguchi A, Kasuga M (1995) Localization and subcellular distribution of SH-PTP2, a protein-tyrosine phosphatase with Src homology-2 domains, in rat brain. Biochem Biophys Res Commun 211: 950–959.

14. Servidei T, Bhide PG, Huang Z, Moskowitz MA, Harsh G, et al. (1998) The protein tyrosine phosphatase SHP-2 is expressed in glial and neuronal progenitor cells, postmitotic neurons and reactive astrocytes. Neuroscience 82: 529–543.

15. Aoki Y, Huang Z, Thomas SS, Bhide PG, Huang I, et al. (2000) Increased susceptibility to ischemia-induced brain damage in transgenic mice overexpressing a dominant negative form of SHP2. FASEB J 14: 1963–1973.

16. Chong ZZ, Lin SH, Kang JQ, Maese K (2003) The tyrosine phosphatase SHP2 modulates MAP kinase p38 and caspase 1 and 3 to foster neuronal survival. Cell Mol Neurobiol 23: 561–578.

17. Park SJ, Kim HY, Kim H, Park SM, Joe EH, et al. (2009) Oxidative stress induces lipid raft-mediated activation of Src homology 2 domain-containing protein-tyrosine phosphatase 2 in astrocytes. Free Radic Biol Med 46: 1694–1702.

18. Yun JH, Park SJ, Jo A, Kang JL, Jou I, et al. (2011) Caveolin-1 is involved in reactive oxygen species-induced SHP-2 activation in astrocytes. Exp Mol Med 43: 660–668.

19. Kim JW, Lee CS, Lee JH, Lee JW, et al. (2010) Lipid raft proteome reveals that oxidative phosphorylation system is associated with the plasma membrane. Expert Rev Proteomics 7: 849–866.

20. Williams TM, Lisanti MP (2005) Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 288: C949–506.

21. Cameron PL, Ruffin JW, Bollag R, Rasmussen H, Cameron RS (1997) Identification of caveolin and caveolin-related proteins in the brain. J Neurosci 17: 9520–9533.

22. Cao H, Courchesne WE, Mastick GC (2002) A phosophotyrosine-dependent protein interaction screen reveals a role for phosphorylation of caveolin-1 on tyrosine 14: recruitment of C-terminal Src kinase. J Biol Chem 277: 8771–8774.

23. Couet J, Li S, Okamoto T, Ikezu T, Lisanti MP (1997) Identification of peptide interaction screen reveals a role for phosphorylation of caveolin-1 on tyrosine 14: recruitment of C-terminal Src kinase. J Biol Chem 272: 6325–6333.

24. Gonzalez E, Nagiel A, Lin AJ, Golan DE, Michel T (2004) Small interfering RNA-mediated down-regulation of caveolin-1 differentially modulates signaling pathways in endothelial cells. J Biol Chem 279: 40659–40669.

25. Okada M, Nakagawa H (1989) A protein tyrosine kinase involved in regulation of pp60-src activity. J Biol Chem 264: 20896–20899.

26. Ma Z, Qin H, Benveniste EN (2001) Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-gamma and IFN-beta: critical role of STAT-1alpha. J Immunol 167: 5150–5159.

27. Biagini RE, Scholtmann SA, Sammons DL, Smith JP, Snawder JC, et al. (2003) Method for simultaneous measurement of antibodies to 23 pneumococcal capsular polysaccharides. Clin Diagn Lab Immunol 10: 744–750.

28. Vega S, Sribner WM, Natarajan V (1997) Activation of protein phosphorylation by oxidants in vascular endothelial cells: identification of tyrosine phosphorylation of caveolin. Free Radic Biol Med 22: 25–35.

29. Zheng J, Wen Y, Chen DR, Bird IM, Magness RR (2005) Angiotensin II elevates nitric oxide synthase 3 expression and nitric oxide production via a mitogen-activated protein kinase cascade in ovine femoral arterial endothelial cells. Biol Reprod 72: 1421–1428.

30. Sun Y, Hu G, Zhang X, Minshall RD (2009) Phosphorylation of caveolin-1 regulates oxidant-induced pulmonary vascular permeability via paracellular and transcellular pathways. Circ Res 105: 676–685.

31. Kim YN, Dam P, Bertics PJ (2002) Caveolin-1 phosphorylation in human squamous and epidermoid carcinoma cells: dependence on ErbB1 expression and Src activation. Exp Cell Res 280: 134–147.

32. Place AT, Chen Z, Bakhshi FR, Liu G, O’Bryan JP, et al. (2011) Cooperative role of caveolin-1 and C-terminal Src kinase binding protein in C-terminal Src kinase-mediated negative regulation of c-Src. Mol Pharmacol 80: 665–672.

33. Soderberg O, Leuchowsius KJ, Guilbarg M, Jarvis M, Weihbrecht I, et al. (2008) Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay. Methods 45: 227–232.

34. Salmoud RJ, Alexander DR (2006) SHP2 phosphatase: a new player in the immune system. Trends Immunol 27: 154–160.

35. You M, Yu DH, Fung GS (1999) Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol Cell Biol 19: 2416–2424.

36. Gupta VK, You Y, Kliotomer A, Graham SL (2012) Ship-2 regulates the TrkB receptor activity in the retinal ganglion cells under glaucomatous stress. Biochim Biophys Acta 1822: 1643–1649.

37. Arnaud M, Maal R, Gesher E, Crouin C, Guenzu C, et al. (2004) Interaction of the c-fos serum response element by interferon-2. Biochem J 382: 543–556.

38. Cai T, Nishida K, Hirano T, Khavari PA (2002) Gab1 and SHP-2 promote Ras/MAPK regulation of epidermal growth and differentiation. J Cell Biol 159: 103–112.

39. Razani B, Woodman SE, Lisanti MP (2002) Caveolae: from cell biology to animal physiology. Pharmacol Rev 54: 431–467.

40. Sun SY (2010) N-acetylcysteine, reactive oxygen species and beyond. Cancer Biol Ther 9: 109–110.

41. Saha H, Okada M, Nakagawa H, Hanafina H (1992) Activation of c-Src in cells bearing v-Crk and its suppression by Csk. Mol Cell Biol 12: 4706–4713.

42. Ha CH, Bennett AM, Jin ZG (2008) A novel role of vascular endothelial cadherin in modulating c-Src activation and downstream signaling of vascular endothelial growth factor. J Biol Chem 283: 7261–7270.

43. Parson JT (2003) Focal adhesion kinase: the first ten years. J Cell Sci 116: 1409–1416.

44. Thomas JW, Ellis B, Boerner RJ, Knight WB, White GC, 2nd, et al. (1998) SH2- and SH3-mediated interactions between focal adhesion kinase and Src. J Biol Chem 273: 577–583.

45. Ren Y, Meng S, Mei L, Zhao ZJ, Jove R, et al. (2004) Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor. J Biol Chem 279: 8497–8505.